Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma.
Ortiz-Ruiz A, Ruiz-Heredia Y, Morales ML, Aguilar-Garrido P, García-Ortiz A, Valeri A, Bárcena C, García-Martin RM, Garrido V, Moreno L, Gimenez A, Navarro-Aguadero MÁ, Velasco-Estevez M, Lospitao E, Cedena MT, Barrio S, Martínez-López J, Linares M, Gallardo M. Ortiz-Ruiz A, et al. Among authors: valeri a. Cancers (Basel). 2021 Apr 1;13(7):1662. doi: 10.3390/cancers13071662. Cancers (Basel). 2021. PMID: 33916196 Free PMC article.
Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma.
Gutiérrez-González A, Martínez-Moreno M, Samaniego R, Arellano-Sánchez N, Salinas-Muñoz L, Relloso M, Valeri A, Martínez-López J, Corbí ÁL, Hidalgo A, García-Pardo Á, Teixidó J, Sánchez-Mateos P. Gutiérrez-González A, et al. Among authors: valeri a. Blood. 2016 Nov 3;128(18):2241-2252. doi: 10.1182/blood-2016-01-695395. Epub 2016 Sep 13. Blood. 2016. PMID: 27625360 Free article.
Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma.
Alonso R, Cedena MT, Gómez-Grande A, Ríos R, Moraleda JM, Cabañas V, Moreno MJ, López-Jiménez J, Martín F, Sanz A, Valeri A, Jiménez A, Sánchez R, Lahuerta JJ, Martínez-López J. Alonso R, et al. Among authors: valeri a. Am J Hematol. 2019 Aug;94(8):853-861. doi: 10.1002/ajh.25507. Epub 2019 Jun 9. Am J Hematol. 2019. PMID: 31074033 Free article.
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. Alonso R, et al. Among authors: valeri a. Blood Adv. 2020 May 26;4(10):2163-2171. doi: 10.1182/bloodadvances.2020001508. Blood Adv. 2020. PMID: 32433744 Free PMC article.
Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
Sevilla-Movilla S, Arellano-Sánchez N, Martínez-Moreno M, Gajate C, Sánchez-Vencells A, Valcárcel LV, Agirre X, Valeri A, Martínez-López J, Prósper F, Mollinedo F, Teixidó J. Sevilla-Movilla S, et al. Among authors: valeri a. J Pathol. 2020 Sep;252(1):29-40. doi: 10.1002/path.5480. Epub 2020 Jul 22. J Pathol. 2020. PMID: 32501543 Free article.
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, Martin T, Wolf J, Lahuerta JJ, Martinez-Lopez J. Cedena MT, et al. Among authors: valeri a. PLoS One. 2020 Aug 31;15(8):e0237155. doi: 10.1371/journal.pone.0237155. eCollection 2020. PLoS One. 2020. PMID: 32866200 Free PMC article.
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. Leivas A, et al. Among authors: valeri a. Blood Cancer J. 2021 Aug 14;11(8):146. doi: 10.1038/s41408-021-00537-w. Blood Cancer J. 2021. PMID: 34392311 Free PMC article.
Overcoming tumor resistance mechanisms in CAR-NK cell therapy.
Valeri A, García-Ortiz A, Castellano E, Córdoba L, Maroto-Martín E, Encinas J, Leivas A, Río P, Martínez-López J. Valeri A, et al. Front Immunol. 2022 Aug 3;13:953849. doi: 10.3389/fimmu.2022.953849. eCollection 2022. Front Immunol. 2022. PMID: 35990652 Free PMC article. Review.
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena MT, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J, Barrio S. Jiménez-Ubieto A, et al. Among authors: valeri a. Front Immunol. 2023 Jun 5;14:1188818. doi: 10.3389/fimmu.2023.1188818. eCollection 2023. Front Immunol. 2023. PMID: 37342332 Free PMC article.
425 results